LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative Metastatic Breast Cancer
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Are progression-free and disease-free survival the new gold standard for cancer trials? | Cancer World Archive
Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Kaplan-Meier analysis of (a) progression-free survival (PFS); and (b)... | Download Scientific Diagram
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Progression-Free Survival (PFS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
Progression-Free Survival for WM | IMBRUVICA® (ibrutinib)
Progression-free survival (PFS) and overall survival (OS) time. Median... | Download Scientific Diagram
Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis | PLOS ONE
Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)
Kaplan-Meier curve of median progression-free survival (PFS) and... | Download Scientific Diagram
Overall survival and progression-free survival. The median follow-up... | Download Scientific Diagram
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
IMFINZI® (durvalumab) Efficacy & Clinical Trials for ES-SCLC
NEJM on Twitter: "KEYNOTE-836: In advanced cervical cancer, median PFS was 10.4 months with pembrolizumab and 6 months with placebo. Overall survival at 2 years was 50.4% and 40.4%, respectively. #ESMO21 https://t.co/sZd6SFiGKd
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Median overall survival (OS) and progression-free survival (PFS) in a... | Download Scientific Diagram
Kaplan-Meier curves of progression-free survival (PFS) and overall... | Download Scientific Diagram
A) Overall survival (OS) and (B) progression-free survival (PFS).... | Download Scientific Diagram
